Connect with us
  • Elysium


Clinical trial gives hope to spinal cord injury patients

If successful animal studies translate into patients, NVG-291 could be set to redefine the treatment of spinal cord injury



A revolutionary treatment designed to help redefine the future of people with spinal cord injury (SCI) is to embark on a clinical trial. 

The NVG-291 treatment has previously indicated its huge potential through two independent studies, which resulted in significant recovery in mobility and/or bladder function in animals with spinal cord injury. 

Now, NervGen Pharma, the biotech company behind NVG-291, has announced a Memorandum of Understanding the Shirley Ryan AbilityLab, with the intention of progressing the first clinical trial of the treatment. 

The single site trial is expected to start in the second half of this year and will assess the safety and effect of NVG-291 in treating acute and subacute, as well as chronic SCI, patients. 

NVG-291 is based on the by Dr Jerry Silver at Case Western Reserve University of a class of molecules (chondroitin sulphate proteoglycans, or CSPGs) that are up-regulated in response to nervous system damage and that inhibit repair. 

NVG-291 was designed to bypass this inhibition by CSPGs, thereby enhancing the body’s natural repair mechanisms, including plasticity, regeneration and remyelination.

“We have been following Dr Silver’s work for years and are very excited to be the first centre working with NervGen on this important spinal cord injury study,” said Dr Monica A. Perez, scientific chair of the Arms + Hands Lab at Shirley Ryan AbilityLab.

“One of the important aspects of this single-centre, placebo-controlled trial is the use of advanced electrophysiology to assess transmission in cortical and subcortical neuronal pathways as well as behavioural outcomes. 

“The ability of NVG-291 to demonstrate meaningful recovery in motor function, sensory function and bladder control in animal models is exceptional. 

“If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.”

“NervGen and Shirley Ryan AbilityLab are planning a very unique and intriguing trial design, into which I have been fortunate to provide input,” stated Dr James Guest, professor of neurological surgery at the University of Miami and member of NervGen’s Spinal Cord Injury Clinical Advisory Board.

“The rationale to include acute and chronic patients in a study underscores the broad potential of the mechanism of NVG-291 in SCI. 

“Using Shirley Ryan AbilityLab in a single-centre study that implements advanced electrophysiological techniques to monitor connectivity across the site of injury will allow reproducible testing to explore NVG-291’s effects on motor recovery, possibly shaping the impact of subsequent studies.

“Partnering with Shirley Ryan AbilityLab, a leading institution in spinal cord injury research and management of patients with spinal cord injury, is an exceptional opportunity for NervGen.”


ONWARD makes first human implant of new technology

Trials of its implantable pulse generator (IPG) and HemON study are stepping up efforts to support people living with spinal cord injury



The first in-human use of an implantable pulse generator (IPG) has been made by ONWARD, stepping up its efforts to help change the futures for people with spinal cord injury (SCI). 

Dr Jocelyne Bloch

The ARC IM IPG is designed to stimulate the spinal cord to restore movement and autonomic function for people with SCI and other conditions that impact mobility. 

Its implantation into a human for the first time marks the start of patient enrolment in ONWARD’s HemON Study, which aims to enrol up to 16 participants at Switzerland’s Lausanne University Hospital (CHUV), to evaluate the safety and preliminary efficacy of ARC IM therapy to improve blood pressure management and trunk control in people with SCI. 

Orthostatic hypotension affects around 75 per cent of people with SCI, and is characterised by debilitatingly low blood pressure that may occur when people sit upright, stand, or change body position.

“ONWARD’s ARC IM IPG offers surgeons precision and flexibility never before available in an implantable neurostimulator,” said Dr Jocelyne Bloch, chief of functional neurosurgery at CHUV. 

“Clinicians will be able to leverage these advanced capabilities to refine and deliver epidural stimulation therapies for people with spinal cord injury.”

The IPG and HemON Study build further on the progress of ONWARD in giving hope to people with SCI, with its STIMO-BRIDGE study showing the potential of its ARC IM technology through enabling paralysed people to regain the ability to walk, stand, swim and cycle, supported by intense rehabilitation. 

Its Up-LIFT study, involving 14 leading SCI sites across the UK, United States, Canada and the Netherlands, is gathering the data to prove the efficacy of its ARC EX technology. 

The ONWARD ARC IM IPG was purpose-designed to deliver targeted electrical stimulation to the spinal cord in the precise areas responsible for triggering or controlling movement and autonomic functions that may be affected by a spinal cord injury or neurodegenerative disorder. 

The IPG is designed to operate in closed-loop, incorporating data from sensors or other devices that may be deployed inside or outside the body. 

It is also designed to deliver therapy through an associated ARC IM lead with precision and flexibility, allowing clinicians to apply biomimetic stimulation that can closely replicate normal spinal cord activity patterns during mobility or autonomic function.

“The first implant of our ARC IM IPG is a huge milestone for ONWARD and the SCI community,” said Dave Marver, CEO of ONWARD. 

“This important achievement validates our vision for a future in which clinicians will no longer need to struggle with modified pain stimulators to explore new treatments and instead will be able to use devices and therapies designed specifically to treat people with spinal cord injury and their unique needs.”

Continue Reading


Sports stars support Wings for Life World Run

The event, uniting teams of runners globally, raises money for spinal cord research by Wings for Life Foundation



Internationally-known athletes and sports teams are spearheading the charge to secure teams of runners from around the world to take part in an event to raise vital funds for spinal cord research. 

The Wings for Life World Run brings together people from around the world for an event on Sunday (May 8), where they all join together – physically or virtually, through use of an app – in support of the quest to find a cure for spinal cord injury. 

More than 8,000 teams globally have already signed up for the run, with world-class athletes and teams also committing their support. 

Liverpool and England footballer Trent Alexander-Arnold has committed his support to the Wings for Life World Run. 

Although his playing schedule and Liverpool’s title challenge prevents him from taking part on the day, he urged others to show their support for the work of the Wings for Life Foundation, whose purpose is to find a cure for spinal cord injury, an area where a huge amount of progress is being achieved globally.

“After meeting Emerson Grant in 2019 I have wanted to work out ways to help raise awareness of Wings for Life,” he said.  

“I want to get as many sign-ups for my team as possible to raise more money for Wings for Life to support their aim of finding a cure for spinal cord injury.”

Also throwing their support behind the Wings for Life World Run are two Formula-1 teams – Scuderia AlphaTauri and Oracle Red Bull Racing. The motorsport teams have been encouraging their large fan followings to sign up and take part in the global race for the good cause.

Two leading Greek athletes — Dimitris Kyrsanidis and Nikolas Plytas — and three Olympians from Norway – world record holder and Olympic gold medalist (110m hurdles) Karsten Warholm, double Olympic champion in cross-country skiing Petter Northug, and triathlete and Olympic champion Kristian Blummenfelt – will all be taking part. 

Florian Neuschwander

German ultra runner and team captain Flo Neuschwander, who organised the largest team ever last year with 3,061 participants, is now looking to improve on his achievement.

“The Wings for Life World Run is a tremendous highlight for me every year. I feel like I’m always try to push myself beyond my limits in this event,” he said. 

“In 2020, I managed to run the fastest pace ever in a race, even though I was running all by myself with the app. 

“But to be honest my biggest goal at the Wings for Life World Run is to lead the biggest team again. 

“Since 2016 the ‘Run with the Flow Team’ has been the winning team and last year we managed even to run 45,000 kilometers collectively, which means we actually ran one lap around the world together on race day. 

“The more runners, the more donations – and that, along with being part of a super day of running, is the biggest goal for all of us who take part in this great event.”

The Wings for Life World Run enables people to run collectively, wherever they are in the world, at exactly the same time. 

Participants run as far as possible until the Catcher Car passes them, with 100 per cent of the entry fee going into the work of the Wings for Life Foundation into spinal cord research. 

For more information and registration, visit

Continue Reading


Christopher & Dana Reeve Foundation appoint new senior figure

Dr Marco Baptista joins as chief scientific officer, moving from the Michael J. Fox Foundation



A leading figure in neuroscience has joined the Christopher & Dana Reeve Foundation to help lead its mission to advance cures for spinal cord injury (SCI) and paralysis. 

Dr Marco Baptista joins as Chief Scientific Officer and will provide scientific and innovative oversight of the nonprofit’s collaborative approach to accelerating the field toward meaningful therapeutics.

Dr Baptista joins the Reeve Foundation as it celebrates 40 years of progress and the seismic shift that it helped steer to move the field of SCI research to its current fast-developing state.

To date, the Foundation has funded more than $140million of research around the world, uniting the brightest minds in the field to help usher a new era of scientific inquiry focused on developing and delivering treatments that are, today, pushing the world toward real cures.

“What began as a grassroots movement by pioneers who refused to accept the long-standing dogma that the spinal cord, once injured, could never be repaired is today an exciting field primed to cross the critical threshold of laboratory science to real-world therapies widely available to our community,” said Maggie Goldberg, President and CEO of the Reeve Foundation. 

“Dr Baptista brings a special blend of neuroscience acumen to our organization, our research collaborative and the community of people living with or caring for someone with SCI. His strong industry knowledge will move us from the bench to the bedside. We’re honored to have him aboard.”

Dr Baptista joins the Reeve Foundation from the Michael J. Fox Foundation for Parkinson’s Research, where he served as Vice President of Research Programs. 

Dr Marco Baptista

In his decade with the Fox Foundation, he led priority research around LRRK2, a major genetic mutation that can increase the chances of developing Parkinson’s disease – an area of study that had also been the focus of his efforts in the pharmaceutical industry, where he spent five years working at Schering-Plough, and then Merck when it acquired the company in 2009. 

“Joining the Reeve Foundation is a natural extension of my long and deep commitment both to studying the central nervous system and my desire to help people,” said Dr Baptista. 

“With the Foundation’s reputation and impact in care and scientific research for those living with SCI, it’s an exciting place to be at the right moment in time.

“The Reeve Foundation took this field from obscurity to one of real promise. Now, thanks in part to its funding of basic research, we’ve generated a solid understanding of the biological mechanisms underlying SCI and paralysis, and the drive toward cures is not a hammer looking at all the world as a nail. 

“Rather, we can identify the studies that stand the greatest chances of success, learn quickly from those that fail, and remove barriers to our greatest shared goal: long-awaited cures.”

In his new role, Dr Baptista will manage the Foundation’s research portfolio, which includes a number of high-profile endeavours with the potential to swiftly move the needle toward clinically approved and market-ready products. These include:

  • The Big Idea, a groundbreaking study at the University of Louisville investigating epidural stimulation to dramatically improve quality of life through improved cardiovascular health, bladder control, and other autonomic functions – and voluntary movement, including the previously impossible task of walking over ground. The trial is on track to be fully enrolled this summer.
  • Research-driven financial investments, such as a partnership with ONWARD, a Netherlands-based company that has developed breakthrough technology currently in global clinical trials that deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions; and Axonis, an emerging biotech advancing breakthrough research to develop therapies for neurological disorders.
  • A strategic partnership with the UK’s International Spinal Research Trust (ISRT) to co-develop a research strategy with a joint focus on chronic injury, combination approaches and clinical translation. At the core of the alliance is a collaborative blueprint that aims to establish a framework for decision-making, planning and governance to advance the most promising therapies from the preclinical stage through clinical trials and into medical practice. Most recently, the Reeve Foundation and ISRT announced joint funding for a newly created translational award totaling $1.3 million, focused on restoring function in chronic SCI through novel circuit formation.
  • Support for the North American Clinical Trials Network (NACTN), a research network established by the Foundation that to date has enrolled more than 1000 subjects to a data registry; it also actively collaborates with other clinical trial networks in Europe and Canada. Dr. Baptista will liaise with the principal investigators leading this important, ongoing research.


Continue Reading


Sign up for the NR Times newsletter
I would like to receive by email other offers, promotions and services from Aspect Publishing Ltd and its group companies.*